Chengdu-based, generative artificial intelligence (AI)-driven clinical stage biotech company, Insilico Medicine, has announced the receipt of a $10 million clinical milestone payment from Exelixis following the progress of its XL309 (ISM3091) project in the clinical stage. XL309 is a selective, oral USP1 small molecule inhibitor discovered by Insilico Medicine using its proprietary AI platform and subsequently licensed to Exelixis in 2023.
Therapeutic Potential of XL309 in nAMD
XL309 has demonstrated potential efficacy in preclinical studies across multiple HRD and non-HRD tumor cell lines, showing strong anti-proliferative activity and excellent selectivity in BRCA-mutated tumor cells and homologous recombination repair models. The Phase I clinical trial, led by Exelixis, is currently underway in the United States to assess the safety, tolerability, and preliminary efficacy of XL309 as a monotherapy and in combination with other treatments in patients with specific late-stage solid tumors.
Implications of the Milestone Payment
The milestone payment not only signifies the recognition of Insilico Medicine’s research and development efforts, but also highlights the potential of XL309 in the treatment landscape of neovascular age-related macroscopic degeneration (nAMD) and other advanced malignancies. This achievement underscores Insilico Medicine’s commitment to leveraging AI-driven drug discovery to accelerate the development of novel therapeutics for unmet medical needs.-Fineline Info & Tech
